Evaluation of Traditional Medicines III: The Mechanism of Immune Modulation by PHELA. by Lekhooa, Makhotso et al.
Lekhooa et al., Afr J Tradit Complement Altern Med. (2012) 9(5S):47-63 
 
 
47
Evaluation of Traditional Medicines III: The Mechanism of Immune Modulation by PHELA.  
 
Makhotso Lekhooa*, Andrew Walubo*, Jan JB Du Plessis*, and Motlalepula G. Matsabisa#1 
 
*University of the Free State, Department of Pharmacology 
1Medical Research Council, Indigenous Knowledge Systems (Health) Unit 
P.O.Box 19070, Tygerberg 7505, Francie van Zijl Drive Parow Valley, Cape Town, South Africa 
 
# E-mail: motlalepula.matsabisa@mrc.ac.za 
 
Abstract 
 
PHELA is a herbal traditional medicine that is under development for use as an immune booster in immune compromised 
individuals. Therefore, the aim of this study was to determine PHELA’s mechanism of action by observing for changes in cytokine profiles. 
Four groups of Sprague Dawley rats (n = 8) were treated daily and separately with normal-saline, cyclosporine-A, PHELA-only and PHELA+ 
cyclosporine-A. Thereafter, 4 animals from each group were sacrificed after 7 and 14 days of treatment. Serum Th1 cytokines (IL-2, IFN-γ 
and TNF-ά) and Th2 cytokines (IL-4 and IL-10) were measured by ELISA. The concentrations of Th1 cytokines in the PHELA-only treated 
group were similar to the control group on days 7 and 14. However, the Th1 cytokines were higher in the PHELA+cyclosporine-A treated 
group compared to cyclosporine-A group, and cyclosporine-A concentrations were similar in both groups. These results show that PHELA 
did not stimulate Th1 cytokines of a normal immune system but stimulated them when the immune system was suppressed by cyclosporine-
A. In conclusion, PHELA is an immune-stimulant to a compromised immune system. 
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Introduction 
The human immunodeficiency virus (HIV) is a retrovirus that leads to acquired immunodeficiency syndrome (AIDS).  HIV infects 
the immune sytem, making the host unable to control the virus and at the same time more susceptible to infections by other pathogens.  It 
targets the major immune cells, CD-4 T cells, macrophages and microglial cells.  Symptomatic HIV infection is characterized by 
emergence of opportunistic infections and cancers in different body systems that the immune system would normally prevent.   
Since the first cases of acquired immunodeficiency syndrome (AIDS) were reported in 1981, the infection has grown to 
pandemic proportions, resulting in an estimated 65 million infections and 25 million deaths globally.  In 2008, about 33.4 million people 
were living with HIV, of whom 2.7 million more people were newly infected with HIV and 2.0 million die of AIDS (UNAIDS, 2009).  Although 
HIV and AIDS are found in all parts of the world, some areas are more afflicted than others. The worst affected region is the sub-Saharan 
Africa, where in some countries, more than one in five adults is infected with HIV.  South Africa experienced one of the most severe AIDS 
epidemics in history whereby by the end of 2008, there were 5.7 million people living with HIV in South Africa (UNAIDS, 2008).   
On the other hand, the use of anti-retroviral (ARV) drugs has lead to decreased HIV related morbility and mortality (WHO et al, 
2009). Unfortunately, the ARV drugs do not cure the disease and are not accessible to all patients that need them (WHO et al, 2010). Also 
ARV drugs can cause adverse effects that include metabolic disorders and these worsen with chronic therapy (Carr and Cooper, 2000). 
This implies that ARV drugs are not the sole solution to eradication of the virus. However, it is well established that improvement during 
ARV drug therapy is paralleled with improved immune response, which highlights the need for boosting the immune system in controlling 
progression of HIV disease (Vicenzi and Biswas, 1997). There is a need for immune boosters that can enhance and stimulate the immune 
system and, if possible, to be used in combination with ARV drugs. 
PHELA is a name given to the herbal mixture of four African traditional medicinal plants [Clerodendrum glabrum, Polianthes 
tuberosa, Rotheca myricoides and Senna occidentails] which has been traditionally used as remedies for wasting conditions, energy 
booster  and some traditional health practitioner claim that these plants can help HIV/AIDS patients (Tshikalange et al, 2008). A sub-
chronic toxicology study of PHELA in vervet monkeys showed no toxic effects on the test animals. In a phase I clinical trial in healthy 
human participants, no toxicity was observed [Medical Research Council, Indigenous Knowledge Systems Lead Programme report, 2009].  
Clinical Observation study conducted using PHELA as an immune booster in 500 HIV/AIDS patients revealed an increase in the patient's 
appetite, 23% weight gain, 80% decrease in viral load and 200% increase in CD4 cell counts. Moreover, the overall quality of life of 
patients was increased from 30% to 100% (Matsabisa et al, 2006. An observational study of HIV positive and AIDS patients taking PHELA, 
a traditional Medicine,  at  Philisa Health Care Centre in Mabopane, North West province, South Africa from 2003 to 2005. Internal Report, 
MRC, South Africa). The latter has lead MRC-IKS into developing PHELA as an immune booster in HIV patients. 
Unfortunately, the mechanism of action of PHELA on the immune system is not known. However, it is well known that the 
immune cells are regulated by cytokines and that the cytokine profile determines the type of immune response to any antigen (Romagnani, 
1991; Hayney and Muller, 2003). Activation of type 1 helper T cell (Th1) leads to formation and activation of cytotoxic T-cells thereby 
conferring cell mediated immunity (CMI), while activation of type 2 Th cells (Th2) leads to formation and activation of B-cells for antibody 
response, which confers humoral immunity. The communication between the Th cells and the effector cytotoxic T cells or B cells is through 
cytokines. The Th1 cells produce interferon-gamma (IFN-γ) and interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α), while Th2 cells 
produce interleukin-4 (IL-4) and interleukin-10 (IL-10). Therefore, it was envisaged that by observing changes in cytokine profiles, 
important information on the status of the immune system can be revealed and used to determine the mechanism of action of PHELA. 
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Specifically, the aim of this study was to determine the effect of PHELA on the immune system by observing for subclinical changes in Th 1 
cytokines (IL-2, IFN-γ, TNF-α) that would enhance cell mediated immunity and Th 2 cytokines (IL-4 and IL-10) that would enhance the 
humoral response, with a hope that understanding the mechanism of action will help in designing immune booster therapy.  
 
METHODS 
 
PHELA was manufactured and supplied by the Indigenous Knowledge (IKS) Unit of the South African Medical Research 
Council. In our laboratory, PHELA powder was reconstituted for oral use by dissolving appropriate amounts in normal saline and filtration 
through a millpore membrane with pore size of 30 μm. Sterile normal saline (Euro-Med Laboratories Inc., Cavite, Philippines) and Influenza 
vaccine, Influvac subunit 2009® (Solvay Pharm. Pty Ltd, Johannesburg, South Africa) were purchased from a local pharmacy. The Influvac 
subunit 2009 contained 30 ug/ml of surface antigens of each the strains; A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007 (H3N2) and 
B/Florida/4/2006. Cyclosporine was purchased from Sigma Aldritch Chemical Co. (St Loius, MI, USA). Enzyme-linked immunosorbent 
assay (ELISA) kits, Endogen®, for rat TNF-α, IFN-γ and IL-10 were purchased from Pierce Biotechnology, Inc. (Rockford, IL, U.S.A), while 
the ELISA kits for IL-2 and IFN-γ were from Bender MedSystems (Vienna, Austria), and  the rat IL-4 ELISA Set BD OptEIA™ was from BD 
Biosciences Pharmingen (San Diego, CA, USA).  
 
Animal care 
Ethical approval was obtained from the Animal Ethics Committee of the University of the Free State.  Sprague-Dawley (SD) rats 
weighing 260 – 400 g were used.  Animals were kept and treated at the Animal House of the University of the Free State where they were 
cared for by qualified staff according to International animal care guidelines. They were fed on Standard rat chow and water ad libitum, and 
the cages were cleaned twice a week. During treatment, animals were inspected for skin lesions and other visible adverse events every 
day.   
 
Experimental design 
The animals were divided into six groups whereby four groups had 8 rats each while the fifth group had 12 rats and the sixth 
group 4 rats. The four groups were treated daily with either normal-saline orally (control), cyclosporine 2 mg/kg in olive oil, subcutaneously 
(Cys: negative control), PHELA 15.4 mg/kg orally (test-group-1), and PHELA+cyclosporine (PHELA+Cys: test-group-2). Thereafter, 4 
animals from each group were sacrificed after 7 and 14 days of treatment. The fifth group was inoculated once intramuscularly (laterally on 
the thigh) with influenza vaccine 0.2 ml (positive control) after which 4 animals were sacrificed after 7, 14 and 21 days. The sixth was not 
treated with anything (untreated), hence, was used to determine the status of immune system at base line (i.e., in unmanipulated animals).  
 
Surgical procedure and blood collection and analysis 
Under ether anaesthesia, blood (8-10 ml) was drawn via cardiac puncture and immediately aliquoted into the appropriate test-
tubes. The rat was sacrificed by exsanguination whilst still under anaesthesia.  Blood was collected for liver function tests and full blood 
count, PHELA concentration and cytokine analysis. Liver and renal functions tests and the full blood count were done by Pathcare Vetinary 
Laboratory (Bloemfontein, South Africa), while PHELA concentrations were measured by HPLC using a method developed in our 
laboratory and cyclosporine was analyzed by fluorescent Polarization Immuno-Assay (FPIA) using a Kit (cyclosporine assay for whole 
blood) according manufacturer’s instruction (.Abbots Laboratories., Abbot Park, IL, USA).  Serum cytokines, rat IL-2, IFN-γ, TNF-α, IL-4 
and IL-10 were measured by ELISA on a UV-spectrophotometry with a microplate reader (HP, USA) and according to the manufacturer’s 
instruction.  
 
Data analysis 
The response of cytokines to the treatment with different agents was evaluated by analysing the reponse pattern in the Th1 
cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and IL-10) versus the respective controls. Data was analyzed by non-parametric 
methods using the GraphPad Instat statistical program. Accordingly, summary data were reported as median and range, and the Mann-
Whitney Test was used for data comparison with the level of significance set at p < 0.05.    
 
Results 
Physiological parameters 
 
Table 1 shows the changes in animals’ weights, the liver and renal function tests over the treatment period. The change in 
weight was 0 – 1.8% in the first week, 1 – 5.5% in the second week, and 8.5% in the third week. This was within the expected range for 
age and all the changes in the different groups were similar to those of the control group. Also these changes in weight at 7 and 14 days 
did not warrant a change in drug dosage, while dosing was not applicable at 21 days after influenza vaccination because the vaccine was 
given once. Also, the liver function indicated by the ALT and ALK, and the renal function indicated by creatinine and urea, were normal. 
Table 2 and 3 illustrate the full blood count data. In Table 2, there were no changes in the WBC on the three occasions. However, Table 3 
shows that there was significant reduction in the platelet count in the cyclosporine group on day 7 and 14, and this was antagonized by 
PHELA in the PHELA + cyclosporine group. 
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Cytokines profiles 
The effects of the different agents on the Th1 and Th2 cytokines tended to be more pronounced at 7 days of therapy. 
Thereafter, the cytokine levels in most cases either returned to baseline or were similar to those in the control group, most probably owing 
to endognous immune adjustments.  
 
Influenza vaccine 
Figure 1 shows that the effect of Influenza vaccine on Th1 cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and IL-10) 
was not different from the control. However, the response to influenza vaccine treatment exhibited a trend whereby there was a raise in the 
levels of Th1 cytokines (IL-2, IFN-γ and TNF-α) at 7 days followed by a progessive drop and return to base line, while the Th2 cytokines 
(IL-4 and IL-10) exhbited a downward trend without return to base line.  
 
Cyclosporine 
Figure 2 shows that treatment with cyclosporine lead to a reduction in the levels of Th1 cytokines (IL-2, IFN-γ and TNF-α), and 
this was statistically significant for IL-2 at 7 days of treatment (P = 0.0357).  Regarding Th2 cytokines, cyclosporine lead to a sharp raise in 
IL-10 at 7 days after which it returnred to baseline at 14 days of treatment. The corresponding concentrations of cyclosporine were 38 (38-
42) ng/ml after 7 days and 88 (38 – 116) ng/ml after 14 days of treatment. 
 
PHELA 
Figure 3 shows that the effect of treatment with PHELA on Th1 cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and 
IL-10) was not different from the control. However, the response to PHELA exhibited a trend whereby there was a raise in the Th2 
cytokines levels (IL-4 and IL-10) at 7 days followed by a progressive drop and return to base line. While the TH1 cytokines exhibited an 
upward trend without return to base line. 
 
PHELA + Cyclosporine 
In Figure 4, co-administration PHELA and cyclosporine lead to a reversal of the effects of cyclosporine, i.e., increased levels of 
Th1 cytokines (IL-2, IFN-γ and TNF-α) versus reduced levels of Th2 cytokines (IL-4 and IL-10) at 7 days. Owing to wide variations, only the 
raise in IL-2 was statistically significant (p = 0.0357). The corresponding concentrations of cyclosporine were 66 (52-160) ng/ml after 7 
days and 68 (48 – 76) ng/ml after 14 days of treatment. There was a significant difference between the concentrations cyclosporine only 
group versus those with PHELA+cyclosporine (P = 0.0167) but this was observed by 14 days of treatment (P = 0.2667).  
 
Discussion 
Mechanism of action  
 
As indicated earlier, the cytokine profile determines the type of immune response to any antigen. IIncreased Th1 cytokines lead 
to CMI, while increased Th2 cytokines leads to humoral immunity. In the case of viral infection, the CMI is effective in mediating removal of 
virus-infected cells, while the Th2 cytokines mediate production of antibodies to defend against viral invasion. However, the two cytokines 
must co-exist because they regulate each other regarding their actions whereby Th1 cytokines are pro-inflammatory while the Th2 are anti-
inflammatory, and in their production where some Th1 cytokines inhibit/stimulate release of specific Th2 cytokines and the vice versa.  
Nevertheless, it is suffice to say that traditional medicines that increase Th1 cytokines would be the ideal candidates for 
development as immune boosters against established viral infections, while those that stimulate Th2 cytokines would be ideal for 
preventing viral infections. But, in this study, it has been demonstrated that PHELA acts on the immune system whereby it increased, al 
beit not statstically significant, the Th2 cytokines of a normal immune system at 7 days of treatment and increased or boosted the Th1 
cytokines against cyclosporine induced immune suppression. Boosting in this case refers to the fact that the response to 
phale+cyclosporine treatment, particularly by IL-2, was higher than in the control and PHELA-only groups. This implies that PHELA has a 
dual action on cytokines in that it stimulates the relevant cytokines depending on the situation. The mild-moderate stimulation of Th2 
cytokines of a normal immune system was probably to inhibit Th1 cytokine production and limit inflammation which was successfully 
achieved, while stimulation of Th1 cytokines when they were suppressed by cyclosporine was most appropriate action for the situation. 
Furthermore, this also implies that PHELA’s actions on Th1 cytokines are more pronounced on a suppressed than on a normal immune 
system, which rhymes with the clinical observations studies where PHELA lead to improvement of immune markers in patients with a 
compromised immune system (Matsabisa G.M. and P Yako, 2006. An observational study of HIV positive and AIDS patients taking 
PHELA, a traditional Medicine,  at  Philisa Health Care Centre in Mabopane, North West province, South Africa from 2003 to 2005. Internal 
Report, MRC, South Africa).  
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Table 1: Summary of the weights, and liver and renal function tests data (median {range}) for rats (n =7) after 7, 14 and 21 days of treatment. 
 
 
GROUP            Weight           Liver function tests    Renal function tests 
     Before Rx  After Rx  ∆ wt      ALT  ALK  Creatinine       Urea  
       (g)      (g)  (g)      (U/L)   (U/L)     (mg/dl)        (mg/dl) 
 
7 DAYS OF TREATMENT 
Saline  (control)    396±15  403±17  7.0  54 (51 - 60)   272 (211 – 295) 29 (22 – 59)   7.1 (6.0 – 7.7)  
Influenza vac. (+ve control)   405±11  409±12  4.0  57 (47 – 65)   254 (199 – 284) 41 (27 – 47)   7.1 (6.7 – 7.7)  
Cyclosporine (-ve control)   396±15  400±13  4.0  47 (47 – 50)   327 (233 – 359) 31 (25 – 31)    9.1 (8.2 – 9.2) 
Phela     377±23  379±24  3.0  53 (50 – 91)   293 (192 – 361) 32 (24 – 56)   7.5 (6.8 – 8.7) 
Phela + cyclosporine   405±17  402±20  -3.0  51 (34 – 61)   213 (181 – 242) 37 (27 – 42)   6.6 (6.2 – 7.6) 
 
14 DAYS OF TREATMENT 
Saline (control)    405±18  422±23  17.0  59 (57 – 62)   300 (260 – 327) 26 (20 – 34)   7.5 (6.4 – 8.0) 
Influenza vac. (+ve control)   396±13  411±19  15.0  56 (48 – 84)   263 (239 – 278) 32 (19 – 44)   7.1 (6.4 – 7.8) 
Cyclosporine (-ve control)   392±33  396±1  4.0  36 (36 – 51)   240 (171 – 292) 20 (15 – 37)   7.2 (6.9 – 8.1) 
Phela     402±9  424±12  22.0  55 (52 – 69)   255 (184 – 297) 30 (25 – 40)   6.4 (6.0 – 7.0) 
Phela + cyclosporine   386±20  403±16  17.0  51 (48 – 64)   240 (178 – 290) 33 (27 – 46)   7.2 (5.7 – 7.8)  
 
21 DAYS OF TREATMENT 
Influenza vaccine    388±19  421±21  33.0  56 (53 – 68) 241 (195 – 261) 36 (30 – 44) 7.0 (6.2 – 8.3) 
 
 
 Key: ALT: Alanine transaminase (17.5 – 30.2 U/L), ALK:  Alkaline phosphates (56.8 – 128 U/L); Creatinine (0.2 – 0.8 mg/dl), Urea (15 – 21 mg/dl) 
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Table 2: Summary of White blood cells data {median (range)} after 7, 14 and 21 days treatment. 
 
GROUP    WCC   Neutrophils  Lymphocytes  Monocytes  Eosinophils  Basophils  
    (x103/mm3)  (x103/mm3)  (x103/mm3)  (x103/mm3)  (x103/mm3)  (x103/mm3)   
7 DAYS TREATMENT 
 
Saline    6.5 (3.5 – 8.2)  0.53 (0.63 – 1.37)  5.06 (2.82 – 7.33)  0.06 (0.04 – 0.20)  0.11 (0.02 – 0.14)  0.06 (0.04 – 0.10) 
Influenza vaccine   4.2 (3.6 – 6.0)  0.72 (0.58 – 0.91)  3.49 (2.63 – 4.95)  0.02 (0.02 – 0.14)  0.09 (0.07 – 0.11)  0.04 (0.02 – 0.05) 
Cyclosporine   6.5 (4.6 – 7.0)  0.64 (0.43 – 0.98)  5.14 (3.66 – 6.30)  0.16 (0.16 – 0.26)  0.06 (0.03 – 0.13  0.03 (0.03 – 0.09) 
Phela    4.7(4.1 – 5.9)  0.58 (0.44 – 0.77)  3.59 (3.51 – 4.78)  0.08 (0.04 – 0.18)  0.10 (0.08 – 0.18)  0.05 (0.05 – 0.07) 
Phela + Cyclosporine  3.8 (4.3 – 6.7)  0.53 (0.64 – 0.77)  3.05 (3.33 – 5.58)  0.08 (0.09 – 0.15)  0.05 (0.09 – 0.16)  0.07 (0.05 – 0.08) 
 
14 DAYS TREATMENT 
Saline    4.4 (3.2 – 6.5)  0.61 (0.54 – 0.88)  3.38 (2.49 – 5.39)  0.05 (0.02 – 0.16)  0.04 (0.03 – 0.11)  0.06 (0.04 – 0.12) 
Influenza vaccine   2.0 (4.3 – 5.0)  0.79 (0.11 – 0.91)  3.20 (1.42 – 4.12)  0.04 (0.04 – 0.08)  0.09 (0.04 – 0.11)  0.04 (0.03 – 0.05) 
Cyclosporine   7.5 (3.3 – 9.1)  1.10 (0.46 – 1.35)  5.70 (2.61 – 7.63)  0.19 (0.17 – 0.45)  0.03 (0.03 – 0.07)  0.18 (0.03 – 0.04) 
Phela    3.6 (2.8 – 4.9)  0.54 (0.30 – 0.71)  3.11 (2.16 – 3.70)  0.06 (0.02 – 0.16)  0.08 (0.02 – 0.11)  0.05 (0.04 – 0.17) 
Phela + cyclosporine  5.3 (4.7 – 7.3)  0.92 (0.61 – 1.48)  4.16 (3.59 – 5.87)  0.17 (0.05 – 0.19)  0.09 (0.06 – 0.11)  0.11 (0.06 – 0.16) 
 
21 DAYS TREATMENT 
Influenza vaccine   5.3 (3.6 – 5.9)  0.65 (0.53 – 0.81)  3.87 (0.58 – 4.84)  0.09 (0.03 – 0.30)  0.09 (0.06 – 0.16)  0.09 (0.06 – 0.11) 
 
 
Key: WCC: white cell count, Neutrophils (1.77 – 3.38), Lymphocytes (4.78 – 9.12), Eosinophils (0.03 – 0.08), Monocytes (0.01 – 0.04), Basophils (0.00 – 0.03)  
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Table 3: Summary of Red blood cells data {median (range)} for rats (n =7) after 7, 14 and 21 days treatment. 
 
GROUP     RCC  Haemoglobin  Haematocrit  MCV  MCH  MCHC  Platelet count 
     (x103/mm3)     (g/dl)    (l/l)  (fl)  (pg)  (g/dl)  (x103/ml) 
 
7 DAYS TREATMENT 
Saline      9.1 (8.4 – 9.2) 16.2 (15.2 – 16.4)  0.70 (0.68 – 0.73)  78 (77 - 81) 18  23  1051 (322 - 1154) 
Influenza vaccine    8.7 (2.2 – 9.1) 16.4 (16.2 – 17.3)  0.70 (0.18 – 0.75)  80 (78 – 82) 19 (18 – 19) 23  1105 (213 – 1177) 
Cyclosporine    7.7 (6.4 – 8.0) 15.2 (11.8 – 15.4)  0.69 (0.57 – 0.69)  88 (87 – 89) 19 (18 – 20) 22 (21 – 22)   584 (124 – 1067) 
Phela      8.7 (8.4 – 8.9) 15.8 (15.8 – 16.0)  0.69   79 (78 - 82) 18 (18 - 19) 23  1032 (746 – 1164) 
Phela + Cyclosporine   8.3 (8.1 - 9.1) 15.6 (15.0 – 16.8)  0.68 (0.66 – 0.73)  81 (80 - 81) 19 (18 - 19) 23  1101 (1020-1134) 
   
14 DAYS TREATMENT 
Saline     8.7 (8.0 – 8.9) 16.0 (15 .0 – 16.2)  0.69 (0.66 – 0.71)  80 (79 - 82) 19 (18 - 19) 23 (23 - 24) 1023 (212 – 1174) 
Influenza vaccine    8.7 (6.9 – 9.9) 16.4 (12.8 – 16.9)  0.71 (0.56 – 0.74)  82 (78 – 82) 19 (18 – 19) 23 (23 – 24) 1057 (126 – 1257) 
Cyclosporine    7.6 (7.2 – 8.0) 15.0 (13.6 – 15.3)  0.67 (0.62 – 0.69)  88 (86 – 88) 19 (19 – 20) 22 (22 – 23)     91 (74 – 1186) 
Phela     8.8 (8.3 – 9.3) 16.0 (15.7 – 16.9)   0.69 (0.68 – 0.72)  80 (77 - 82) 19 (18 - 19) 23 (23 - 24) 1005 (427 – 1264) 
Phela + Cyclosporine   8.8 (6.4 – 9.4) 16.3 (15.7 – 18.0)  0.70 (0.48 – 0.75)  78 (75 - 80) 18 (17 - 25) 23 (23-34)  1062 (481 – 2392) 
 
21 DAYS TREATMENT 
Influenza vaccine    8.9 (8.3 – 9.3) 16.0 (15.5 – 16.6)  0.71 (0.67 – 0.73)  79 (78 - 81) 18 (18 - 19) 23  1023 (136 – 1130) 
 
 
Key: RCC:Red cell count , Hemoglobin (11.5 – 16.1g/dl), MCV: Mean corpuscular volume (48 – 70 fl), MCH: Mean corpuscular hemoglobin, MCHC: Mean corpuscular hemoglobin concentration (40 g/dl), Platelet count (150 – 460) 
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Interaction with cyclosporine 
The interaction between PHELA and cyclosporine is unlikely to be a pharmacokinetic interaction as the concentrations of 
cylosporine were not different in the two groups, i.e., cyclosporine group vs. phale+cyclosporine group. The difference in concentrations of 
cylosporine after 7 days of treatment was most probably due to delayed absorption from the subcutaneous injection site in the cyclosporine 
only group. Also, preliminary studies in our laboratory in which the effect of PHELA on the activity of each the five major human drug 
metabolizing cytochrome P450 isoforms (CYP2D6, CYP3A4, CYP1A2, CYP2C19, and CYP2C9) were studied, showed that PHELA had 
no significant effect on the activity of any of these iso-enzymes, especially CYP3A. CYP3A is the enzyme responsible for cyclosporine 
metabolism. Furthermore, treatment of rats with PHELA at the same dose used here for 3 and 7 days had no effect on the activity of rat 
CYP3A and other enzymes, and this was confirmed by quantification of CYP3A by SDS-PAGE and Western Blot method. Therefore, the 
mechanism by which PHELA interacted with cyclosporine is not clear. 
PHELA also antagonized the effect of cyclosporine on platelets. Cyclosporine is known to cause thrombotic thrombocytopenic 
purpura due to its activation of platelet aggregation (Lian, 1980; Grace et al, 1987; Phadke and Bagirath, 2004) and depletion of 
prostacyclin-stimulating factor (Neild et al, 1983; Leithner et al, 1982). Unfortunately, this study did not evaluate for these factors, hence, 
the mechanism by which PHELA prevented the cyclosporine induced thrombocytopenia is not known. 
On the other hand, since PHELA alone had no effect on the Th1 cytokines, one might say that cyclosporine augmented the 
action of PHELA, but this remains to be confirmed. In the same perspective, the effects of PHELA could be considered as not different 
from a dietary supplement which can aid restoration of a pathological situation with no further effect on a normal immune system. Well 
then, the latter calls for a review of the dietary recommendations in immune compromised patients because some foods such as PHELA 
would be more relevant than others.  
Lastly, the findings of this study are also important in the chemotherapy for transplant patients, as they high lighted a potential 
adverse interaction between PHELA and cyclosporine that can lead to graft rejection. Therefore, transplant patients using cyclosporine 
should not use PHELA products.  
 
Optimum Time to evaluate cytokine response 
It was observed that cytokine profiles varied with the time lapse since administration of the drugs. For instance, except in a few 
cases, the response at 7 days was always reversed or weaker by 14th day of treatment. This was most probably because the immune 
system countered the disruption of the respective immune mediators. It could also account for the failure by PHELA to stimulate a normal 
immune system but it was not clear whether the response to PHELA would be more remarkable beyond 14 days. Nevertheless, this study 
has demonstrated that the time period since administration of the test antigen is important for interpretation of cytokine response to 
antigens. It was therefore appropriate in this study to use the response at 7 days as more relevant than at 14 days even though both 
occasions were considered in the analysis. 
 
Positive and negative controls 
Since most studies on cytokine are characterized by wide variations in cytokine response that make, not only interpretation of 
data very difficult, but also cast doubt on the robustness of the experimental methods used, it was decided to include the positive and 
negative controls using drugs which immune response is well characterized, i.e., influenza vaccine and cyclosporine, respectively. The 
conviction was that if the experiment can reproduce the expected response by the two drugs, it would confirm the observations in all other 
groups as robust. 
Regarding the response to influenza vaccine, wide variation in cytokine response to the different Influenza vaccines has been 
reported (Tsai et al., 2005; Krakauer  and Russo, 2001; McElhaney et al, 1995; Mcelhaney et al, 2002; Mcelhaney et al, 1998; McElhaney 
et al, 1992; Tamizifar et al, 1997; Saurwein-Teiss et al, 1998).  Nevertheless, most of these studies demonstrated a raise or no effect on 
Th1 cytokines (IL-2, IL-12, TNF-ά, and IFN-γ) with minimal effect on Th2 cytokines (McElhaney et al, 1995; Mcelhaney et al, 2002; 
McElhaney et al, 1992; Tamizifar et al, 1997; Saurwein-Teiss et al, 1998), while a some have demonstrated a raise in TH2 cytokines as 
well (Virelizier et al, 1974; Mitchell and Callard, 1983).  Also, the response by Th1 cytokines was stronger with whole virus vaccine than 
with subunit vaccines (McElhaney et al, 1995; Saurwein-Teiss et al, 1998). In the current study, Influvacc 2009 is a trivalent subunit 
vaccine which, as expected, induced a mild increase in the Th1 cytokines on day 14 and moderate increase in the Th2 cytokines at day 7. 
Even then, our follow up was for only 21 days, yet it was observed in humans that increase in cytokines after Influenza vaccination may 
reach maximum between 3 and 12 weeks (McElhaney et al, 1995). As such, it is likely that Th1 cytokines could have been higher after 21 
days. Unfortunately, since the age corresponding to 12 weeks in rats is not known, monitoring rats for 12 weeks could not be done 
because the effects of aging may influence response to the influenza vaccine (Krakauer  and Russo, 2001; McElhaney et al, 1995; 
Mcelhaney et al, 2002; Mcelhaney et al, 1998; McElhaney et al, 1992;). In conclusion, in this study, the response to influvaac 2009 was as 
expected; a mild effect on Th1 cytokines and moderate suppression of Th2 cytokines, and this imparted a CMI (Mcelhaney et al, 1998).  
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Figure 1a:  The effect of Influenza vaccine on IL-2, INF-γ, and TNF-α in healthy rats (n = 7) 
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                               Figure 1b:  The effect of Influenza vaccine on IL-4 and IL-10 in healthy rats (n = 7) 
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Figure 2a: The effect of Cyclosporine on IL-2, INF-γ, and TNF-α in healthy rats (n = 7). 
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Figure 2b: The effect of Cyclosporine on IL-4 and IL-10 in healthy rats (n = 7)). 
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Figure 3a: The effect of PHELA on IL-2, INF-γ and TNF-α in healthy rats (n = 7). 
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Figure 3b: The effect of PHELA on IL-4 and IL-10 in healthy rats (n = 7)). 
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Figure 4a:  The effect of PHELA on IL-2, INF-γ and TNF-α during co-administration with cyclosporine in healthy rats (n = 7). 
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Figure 4b: The effect of PHELA on IL-4 and IL-10 during co-administration with cyclosporine in healthy rats (n = 7). 
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Regarding cyclosporine, the current study, like in other studies elsewhere, demonstrated that cyclosporine inhibits production of Th1 
cytokines (Il-2, TNF-ά, IFN-γ) while increasing production of IL-10 with minimal or no effect on IL-4 (Corsini et al, 2006; Alberu et al, 2001; Cho 
et al, 2002; Kim et al, 2000; Andersson et al, 1992; Bonnotte et al, 1996; Kim et al, 2000). Therefore, in spite of the wide variations that might 
have led to lack of statistically significant differences, the observations on the effects of PHELA on the immune system are accurate. In fact, the 
effect of cyclosporine on cytokines, especially IL-10, was suggested to be at transcriptional level because cyclosporine increased the IL-10 
mRNA (Cho et al, 2002). It is therefore most probable that PHELA interacts with cyclosporine at transcriptions level, but this too remains to be 
confirmed. 
In conclusion, using a rat model, it has been demonstrated that PHELA is an immune stimulant that antagonizes the effects of 
cyclosporine with minimal effect on a normal immune system in first 14 days of treatment. This implies that PHELA is an ideal candidate for 
further evaluation and development into an immune booster medication. 
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